A medication approved to ease itching in children with Alagille syndrome, a rare genetic liver disorder, is now showing it can clear disfiguring fatty skin growths and reduce dangerously high cholesterol levels. In a new analysis of clinical trial data, nearly two-thirds of children with visible xanthomas (cholesterol-rich deposits under the skin) experienced improvement after about two years of treatment with Livmarli (maralixibat), according to research published in The Journal of Pediatrics.

What Is Alagille Syndrome and Why Does It Cause These Skin Growths?

Alagille syndrome is a rare inherited condition that disrupts the flow of bile, a digestive fluid produced by the liver. In people with this disease, bile backs up in the liver and bloodstream instead of flowing normally into the intestines. This buildup causes bile acids and cholesterol to accumulate to toxic levels, leading to intense itching and, in many cases, the formation of xanthomas.

These fatty skin deposits are more than just a cosmetic concern. The study found that xanthomas were associated with higher blood levels of cholesterol, bile acids, and liver damage markers, as well as poorer quality-of-life scores. Younger children tended to develop more severe xanthomas, suggesting that early-onset disease may be a risk factor for their formation.

How Does Livmarli Work to Reduce These Growths?

Livmarli works by blocking the recycling of bile acids from the intestines back to the liver, which promotes their excretion in stool instead. This reduces the toxic buildup of bile acids and cholesterol in the liver and bloodstream. The medication is already approved to treat the severe itching that plagues many Alagille patients, but this new analysis reveals additional benefits.

Researchers analyzed data from 63 children with Alagille who received Livmarli across two Phase 2 clinical trials and a long-term extension study. They used a standardized scale called the Clinician Xanthoma Scale (CXS), which rates xanthoma severity from zero (no lesions) to four (severe lesions that substantially limit daily activities).

What Did the Study Find?

The results were striking. At the start of the trials, 43% of children had visible xanthomas. After 96 weeks (about two years) of treatment, the proportion of children with no visible xanthomas increased from 60% to 86%. Among the 14 children who had xanthomas at enrollment and had follow-up data available, nine (64%) experienced a decrease in their xanthoma severity score.

Beyond skin improvements, Livmarli also reduced blood cholesterol and bile acid levels. Children who saw improvements in their xanthomas were generally more likely to experience relief from itching and improvements in overall quality of life.

Steps to Understanding Xanthoma Management in Alagille Syndrome

• Baseline Assessment: Doctors use the Clinician Xanthoma Scale to evaluate the severity and extent of fatty skin growths at the start of treatment, helping track changes over time.
• Bile Acid Monitoring: Regular blood tests measure bile acid and cholesterol levels, which are directly linked to xanthoma formation and overall disease severity in Alagille patients.
• Long-Term Treatment: The study tracked children for approximately two years, showing that sustained treatment with Livmarli leads to measurable improvements in both skin lesions and blood markers.

What Are the Limitations and Next Steps?

The researchers acknowledged that their analysis was limited by a small number of patients and the subjective nature of the xanthoma scale. They called for future studies to identify which children are most likely to develop xanthomas and whether earlier or more targeted treatment could prevent these growths altogether.

"Although itch relief remains Livmarli's primary approved indication, our findings suggest a broader therapeutic potential, specifically in improving disfiguring xanthomas and associated high cholesterol levels," the researchers noted.

Study authors, published in The Journal of Pediatrics

For families managing Alagille syndrome, these findings offer hope that a single treatment can address multiple burdensome symptoms at once. The ability to reduce or eliminate disfiguring skin growths while also lowering cholesterol and improving quality of life represents a meaningful advance in care for this rare genetic liver disease.